Accéder au contenu
Merck

MAB5446

Anti-Neurofilament H (200 kDa) Antibody

CHEMICON®, mouse monoclonal, RMO-24

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
RMO-24, monoclonal
Species reactivity:
human, rat
Application:
ELISA, IHC, IP, WB
Citations:
5
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


Nom du produit

Anti-Neurofilament NF-H Antibody, tail domain (Phosphate dependent), clone RMO-24, ascites fluid, clone RMO-24, Chemicon®

biological source

mouse

Quality Level

antibody form

ascites fluid

antibody product type

primary antibodies

clone

RMO-24, monoclonal

species reactivity

human, rat

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable, immunohistochemistry: suitable, immunoprecipitation (IP): suitable, western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... NEFH(4744)
rat ... Nefh(24587)

Immunogen

Epitope: tail domain (Phosphate dependent)
Rat Neurofilaments

Application

Anti-Neurofilament NF-H Antibody, tail domain (Phosphate dependent), clone RMO-24 detects level of Neurofilament NF-H & has been published & validated for use in ELISA, IP, WB, IH.
Research Category
Neuroscience
Research Sub Category
Neurofilament & Neuron Metabolism

Neuronal & Glial Markers
Western blot. Reacts with the 200 kD NF-H from human.

Immunohistochemistry. The antibody has been used successfully on Bouin′s and alcohol-fixed paraffin-embedded or frozen tissue sections. Formalin-fixed paraffin-embedded tissue sections require pretreatment with trypsin.

Immunoprecipitation

Optimal working dilutions must be determined by end user.

Biochem/physiol Actions

Reacts with Neurofilament Heavy (NF-H), tail domain (phosphate dependent). Dephosphorylation of the NF-H will results in diminished immunoreactivity.

Physical form

Ascites fluid. Liquid.

Preparation Note

Maintain at -20°C in undiluted aliquots for up to 12 months after date of receipt. Avoid repeated freeze/thaw cycles.

Analysis Note

Control
Positive Control: Brain

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Explore all of our products under

ou

Essayez notre Outil de sélection de produits pour affiner vos choix.


Classe de stockage

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



Hirofumi Tokuoka et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 26(45), 11606-11614 (2006-11-10)
The mechanism by which synaptic vesicles (SVs) are recruited to the release site is poorly understood. One candidate mechanism for trafficking of SVs is the myosin-actin motor system. Myosin activity is modulated by myosin light chain kinase (MLCK), which in
Atsushi Sato et al.
Stem cell research, 11(1), 601-610 (2013-05-09)
Glioblastoma is the most common and aggressive primary brain tumor. Glioma stem cells (GSCs) are relatively resistant to chemo-radiotherapy and are responsible for tumor progression and the recurrence of glioblastomas after conventional therapy. Thus, the control of the GSC population
Johnny D Figueroa et al.
Journal of neurotrauma, 29(3), 551-566 (2011-10-06)
Currently, few interventions have been shown to successfully limit the progression of secondary damage events associated with the acute phase of spinal cord injury (SCI). Docosahexaenoic acid (DHA, C22:6 n-3) is neuroprotective when administered following SCI, but its potential as



Numéro d'article de commerce international

RéférenceGTIN
MAB544604053252360169